Novartis to Acquire Avidity Biosciences for US$12 Billion
Novartis will acquire Avidity Biosciences for US$12 billion, expanding its genetic medicine pipeline with Avidity's RNA-based therapeutic platform and rare-disease programs.
The all-cash deal, valued at approximately US$12 billion, will give Novartis full ownership of Avidity's platform and three advanced programs targeting neuromuscular disorders, including:
- Duchenne muscular dystrophy
- Myotonic dystrophy type 1
- Facioscapulohumeral muscular dystrophy
The acquisition underscores Novartis's strategy to expand into rare and genetic diseases amidst increasing competition for its established medicines.
Avidity's innovative platform enables precise delivery of RNA therapeutics to muscle tissue, generating strong industry interest.
Author's summary: Novartis acquires Avidity Biosciences for $12 billion.
More News
- Patrick Mahomes’ immediate words on Travis Kelce after victory in the Chiefs Commanders game
- Dr. Vinay Prasad Doesn’t Realize He’s The Establishment. It’s His Job to Produce Results for the American Public, Not Fluff Donald Trump.
- 'Chainsaw Man - The Movie: Reze Arc' Review — A Beautifully Chaotic Anime
- Gavin Newsom Says He Has 'No Interest' in Appearing on Joe Rogan's Podcast: 'I'm Moving On' | Video
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- Art the Clown Owes One of His 'Terrifier' Victims a Lot of Money
- Bitcoin Miner TeraWulf (WULF) Stock Jumps 25% On AI News
- Why the Informal Sector Is Not a Tax Goldmine - Institute of Development Studies
- Tennis takes first loss in Sweet 16 - Davie County Enterprise Record
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global